Drug Trial Radar · NCT01322490
A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Sep 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,297
Actual
Start
Nov 28, 2011
Primary completion
Sep 25, 2017
Study completion Dec 15, 2017
Sponsor
- Lead sponsor
- Bavarian NordicIndustry
- Sponsor type
- Industry
- First posted
- Mar 24, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether PROSTVAC alone or in combination with GM-CSF is effective in prolonging overall survival in men with few or no symptoms from metastatic, castrate-resistant prostate cancer.
Conditions
- Prostate Cancer Metastatic
Interventions
PROSTVAC-VBiological
PROSTVAC-FBiological
GM-CSFDrug
GM-CSF PlaceboOther
PlaceboBiological
PROSTVAC V/F Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: Randomization through the date of death due to any cause. Subjects were followed up for approximately 6 years from the first subject randomized to the completion of the study.
Locations
220 sites in 16 countries. Site status is shown where the registry gives one.
Alaska Clinical Research Center, Llc
Anchorage, Alaska
Scottsdale Healthcare
Scottsdale, Arizona
Alta Bates Summit Medical Center
Berkeley, California
Cedars-Sinai Medical Center
Los Angeles, California
Prostate Oncology Specialists, Inc.
Marina del Rey, California
Desert Hematology-Oncology
Rancho Mirage, California
San Bernardino Urological Associates
San Bernardino, California
San Diego Clinical Trials
San Diego, California
Sharp Memorial Hospital
San Diego, California
VA San Diego Healthcare System
San Diego, California
Stanford Advanced Medical Center
Stanford, California
University of Colorado
Aurora, Colorado
The Urology Center of Colorado
Denver, Colorado
Washington Cancer Institute
Washington D.C., District of Columbia
South Florida Medical Research
Aventura, Florida
Manatee Medical Research Institute, LLC
Bradenton, Florida
Florida Urology Physicians
Fort Myers, Florida
Lakeland Regional Cancer Center
Lakeland, Florida
Pinellas Urology, Inc.
St. Petersburg, Florida
James A Haley Veteran Affairs Medical Center
Tampa, Florida
Palm Beach Cancer Institute
West Palm Beach, Florida
North Idaho Urology
Coeur d'Alene, Idaho
Jesse Brown VA
Chicago, Illinois
First Urology PSC
Jeffersonville, Indiana
Northern Indiana Cancer Research Consortium
South Bend, Indiana
The Iowa Clinic, PC Iowa Urology
West Des Moines, Iowa
Tulane University
New Orleans, Louisiana
Ochsner Cancer Institute
New Orleans, Louisiana
Maryland Prostate Center
Baltimore, Maryland
Greater Baltimore Medical Center
Baltimore, Maryland
Union Memorial Hospital
Baltimore, Maryland
Walter Reed Army Medical Center
Bethesda, Maryland
National Cancer Institute - Center for Cancer Research
Bethesda, Maryland
Myron Murdock M.D. LLC
Greenbelt, Maryland
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
Mayo Clinic
Rochester, Minnesota
Kansas City VA Medical Center
Kansas City, Missouri
GU Research Network, LLC
Omaha, Nebraska
Nebraska Cancer Specialists
Omaha, Nebraska
Showing 40 of 220 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.